Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve

AIM: We analyzed the association between the modified albumin–bilirubin (mALBI) grade and therapeutic efficacy of atezolizumab plus bevacizumab (Atezo+Bev) for the treatment of unresectable hepatocellular carcinoma (u‐HCC). METHODS: In this retrospective observational study, we included 71 u‐HCC pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomonari, Tetsu, Tani, Joji, Sato, Yasushi, Tanaka, Hironori, Tanaka, Takahiro, Taniguchi, Tatsuya, Asahiro, Morishita, Okamoto, Koichi, Sogabe, Masahiro, Miyamoto, Hiroshi, Muguruma, Naoki, Masaki, Tsutomu, Takayama, Tetsuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939118/
https://www.ncbi.nlm.nih.gov/pubmed/35964253
http://dx.doi.org/10.1002/cam4.5145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939118/
https://www.ncbi.nlm.nih.gov/pubmed/35964253
http://dx.doi.org/10.1002/cam4.5145

Ejemplares similares